(Adnkronos) - “Oggi siamo qui per celebrare un grande successo, che è il lancio di una nuova generazione di un farmaco che aiuta a curare le maculopatie. È un percorso iniziato più di dieci anni fa e che ha portato Bayer a entrare nel campo dell’oftalmologia per la prima volta e sfruttare l'innovazione e la scienza per metterle al servizio delle persone”. Così Arianna Gregis, country division head di Bayer Pharmaceuticals Italy, intervenuta all’incontro “Una nuova opportunità per la gestione della maculopatia”, organizzato a Milano dalla farmaceutica e dedicato alla nuova formulazione aflibercept 8 mg, recentemente adottata in Italia, che migliora la qualità di vita dei pazienti con maculopatie, in particolare la degenerazione maculare neovascolare (nAmd) e l’edema maculare diabetico (Dme).
Category
🗞
NewsTranscript
00:00Bayer has a great commitment to improving people's lives and above all, today we are here to talk about our commitment to improving sight, which is one of the most important organs.
00:18To see means to live better. Today we are here to celebrate a great success, which is the launch of a new generation of drugs that help to cure maculopathy.
00:31It is a journey that for us did not start yesterday, but it started more than 10 years ago. It was a journey that led Bayer to enter the field of ophthalmology for the first time and take advantage of innovation and science to put it at the service of people.
00:48So today is a party, a celebration of an important result and it is also a starting point for us for future results and improvements for patients.
00:59Ophthalmology is a top area for Bayer because it is a sector where science and innovation are fundamentally at the service of people.
01:09Our commitment is not only to develop technological solutions such as new drugs, but to think about everything that is the path of care for people and how we can put ourselves at the service of clinics, the Association of Patients and institutions to bring an improvement to the health system in Italy.
01:30Our commitment is to bring innovation, a concrete innovation. I want to give two examples. An important example is Salvare la Vista Si Può, which is an awareness campaign to help all people understand the importance of preserving a vital organ such as the eye.
01:50I would also like to remind you that as a company we are investing in the development of new skills and we have introduced a new role in Italy within Bayer, which is called Innovation Partner in Ophthalmology,
02:07which has the challenge of not only bringing maximum scientific contribution and scientific support to the community of clinicians, but also being able to manage all those themes of the world of pharmacoeconomy, of Lean Management and of organizational support that can impact the patient's path of care.
02:30So our history in Bayer is linked to innovation and concreteness and this makes us look to the future with optimism that we can continue to have alliances that bring concrete results for people.